journal article·2021-05-20Open access

Empirical relationships between compressive and flexural strength of concrete containing recycled asphalt material for pavement applications using different specimen configurations

C.R. Marín-Uribe, R. Navarro-Gaete

Materiales de Construcción· Volume 71· Issue 342

Abstract

The flexural strength of pavement concrete is generally deduced by testing beams or by applying empirical equations. In this investigation, concrete mixtures were manufactured, incorporating 0, 20, 50 and 100% Reclaimed Asphalt Pavement (RAP), by weight, as a replacement for natural aggregates. The compressive strength was measured using cubic specimens and the flexural strength was measured for three types of specimens; beam, semicircular (SCB) and modified beam. This study proposes logarithmic and power equations that allow the estimation of the flexural strength of a concrete mix that incorporates RAP as a function of its compressive strength. Linear or power models are proposed to predict beam flexural strength from SCB specimens and a logarithmic model for modified beam specimens. Statistical analyses show that the proposed prediction models can be considered sufficiently accurate and their use is justified.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Asphalt Pavement Performance Evaluation · Innovative concrete reinforcement materials · Structural Behavior of Reinforced Concrete

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (47)

Show source-provided references
1. Abnet, C. C., Arnold, M., and Wei, W. Q. (2018). Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360-373. doi: NODOI PMID:NOPMID10.1053/j.gastro.2017.08.023 ↗
2. Agostini, M., Melino, G., and Bernassola, F. (2018). The p53 family in brain disease. Antioxid. Redox Signal. 29, 1-14. doi: NODOI PMID:NOPMID10.1089/ars.2017.7302 ↗
3. Alexandrova, E. M., and Moll, U. M. (2012). Role of p53 family members p73 and p63 in human hematological malignancies. Leuk. Lymphoma 53, 2116-2129. doi: NODOI PMID:NOPMID10.3109/10428194.2012.684348 ↗
4. Arnold, M., Soerjomataram, I., Ferlay, J., and Forman, D. (2015). Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64, 381-387. doi: NODOI PMID:NOPMID10.1136/gutjnl-2014-308124 ↗
5. Bidaud, P., Chasle, J., Sichel, F., Rousseau, S., Petit, P., Pottier, D., et al. (2010). Expression of p53 family members and CD44 in oral squamous cell carcinoma (OSCC) in relation to tumorigenesis. Histol. Histopathol. 25, 331-339. doi: NODOI PMID:NOPMID
6. Bieging, K. T., Mello, S. S., and Attardi, L. D. (2014). Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359-370. doi: NODOI PMID:NOPMID10.1038/nrc3711 ↗
7. Blagih, J., Buck, M. D., and Vousden, K. H. (2020). p53, cancer and the immune response. J. Cell. Sci. 133:, jcs237453. doi: NODOI PMID:NOPMID10.1242/jcs.237453 ↗
8. Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., and Schreiber, S. L. (1995). Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377, 441-446. doi: NODOI PMID:NOPMID10.1038/377441a0 ↗
9. Brunn, G. J., Hudson, C. C., Sekulic, A., Williams, J. M., Hosoi, H., Houghton, P. J., et al. (1997). Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99-101. doi: NODOI PMID:NOPMID10.1126/science.277.5322.99 ↗
10. Budanov, A. V., and Karin, M. (2008). p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134, 451-460. doi: NODOI PMID:NOPMID10.1016/j.cell.2008.06.028 ↗
11. Bykov, V. J. N., Eriksson, S. E., Bianchi, J., and Wiman, K. G. (2018). Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer 18, 89-102. doi: NODOI PMID:NOPMID10.1038/nrc.2017.109 ↗
12. Case, A. J., and Domann, F. E. (2014). Absence of manganese superoxide dismutase delays p53-induced tumor formation. Redox Biol. 2, 220-223. doi: NODOI PMID:NOPMID10.1016/j.redox.2014.01.001 ↗
13. Chen, G., Wang, Z., Liu, X. Y., and Liu, F. Y. (2007). Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J. Surg. 31, 1107-1114. doi: NODOI PMID:NOPMID10.1007/s00268-006-0551-1 ↗
14. Chen, J., Kwong, D. L., Cao, T., Hu, Q., Zhang, L., Ming, X., et al. (2015a). Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis. Esophagus 28, 84-89. doi: NODOI PMID:NOPMID10.1111/dote.12088 ↗
15. Chen, W., Zheng, R., Zeng, H., and Zhang, S. (2015b). The updated incidences and mortalities of major cancers in China, 2011. Chin. J. Cancer 34, 502-507. doi: NODOI PMID:NOPMID10.1186/s40880-015-0042-6 ↗
16. de Assis, L. V., and Isoldi, M. C. (2014). The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms. Tumour Biol. 35, 889-901. doi: NODOI PMID:NOPMID10.1007/s13277-013-1210-4 ↗
17. Dubecz, A., Gall, I., Solymosi, N., Schweigert, M., Peters, J. H., Feith, M., et al. (2012). Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J. Thorac. Oncol. 7, 443-447. doi: NODOI PMID:NOPMID10.1097/JTO.0b013e3182397751 ↗
18. Egashira, A., Morita, M., Yoshida, R., Saeki, H., Oki, E., Sadanaga, N., et al. (2011). Loss of p53 in esophageal squamous cell carcinoma and the correlation with survival: analyses of gene mutations, protein expression, and loss of heterozygosity in Japanese patients. J. Surg. Oncol. 104, 169-175. doi: NODOI PMID:NOPMID10.1002/jso.21920 ↗
19. Feng, Z., Zhang, H., Levine, A. J., and Jin, S. (2005). The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. U.S.A.Proceedings of the National Academy of Sciences of the United States of America 102, 8204-8209. doi: NODOI PMID:NOPMID10.1073/pnas.0502857102 ↗
20. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., and Mathers, C. (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer.
21. Gao, Y. B., Chen, Z. L., Li, J. G., Hu, X. D., Shi, X. J., Sun, Z. M., et al. (2014). Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 46, 1097-1102. doi: NODOI PMID:NOPMID10.1038/ng.3076 ↗
22. Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Dicker, D., Pain, A., Hamavid, H., Moradi-Lakeh, M., et al. (2015). The global burden of cancer 2013. JAMA Oncol. 1, 505-527. doi: NODOI PMID:NOPMID
23. Hay, N., and Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945. doi: NODOI PMID:NOPMID10.1101/gad.1212704 ↗
24. Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., et al. (1990). Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the ""hot spot"" mutant phenotypes. Cell Growth Differ. 1, 571-580. doi: NODOI PMID:NOPMID
25. Huang, K., Chen, L., Zhang, J., Wu, Z., Lan, L., Wang, L., et al. (2014). Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma. Oncol. Lett. 8, 1441-1446. doi: NODOI PMID:NOPMID10.3892/ol.2014.2343 ↗
26. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. L. (1990). Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335, 675-679. doi: NODOI PMID:NOPMID10.1016/0140-6736(90)90801-B ↗
27. Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., et al. (2013). Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339. doi: NODOI PMID:NOPMID10.1038/nature12634 ↗
28. Lane, D. P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16. doi: NODOI PMID:NOPMID10.1038/358015a0 ↗
29. Levine, A. J. (2020b). p53: 800 million years of evolution and 40 years of discovery. Nat. Rev. Cancer 20, 471-480. doi: NODOI PMID:NOPMID10.1038/s41568-020-0262-1 ↗
30. Levine, A. J. (2020a). P53 and the immune response: 40 years of exploration-a plan for the future. Int. J. Mol. Sci. 21:, 541. doi: NODOI PMID:NOPMID10.3390/ijms21020541 ↗
31. Levrero, M., De Laurenzi, V., Costanzo, A., Gong, J., Wang, J. Y., and Melino, G. (2000). The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell. Sci. 113( Pt 10), 1661-1670. doi: NODOI PMID:NOPMID10.1242/jcs.113.10.1661 ↗
32. Lin, Y., Totsuka, Y., He, Y., Kikuchi, S., Qiao, Y., Ueda, J., et al. (2013). Epidemiology of esophageal cancer in Japan and China. J. Epidemiol. 23, 233-242. doi: NODOI PMID:NOPMID10.2188/jea.JE20120162 ↗
33. Manzella, L., Stella, S., Pennisi, M. S., Tirro, E., Massimino, M., Romano, C., et al. (2017). New insights in thyroid cancer and p53 family proteins. Int. J. Mol. Sci. 18:, 1325. doi: NODOI PMID:NOPMID10.3390/ijms18061325 ↗
34. Melling, N., Norrenbrock, S., Kluth, M., and Simon, R. (2019). p53 overexpression is a prognosticator of poor outcome in esophageal cancer. Oncol. Lett. 17, 3826-3834. doi: NODOI PMID:NOPMID10.3892/ol.2019.10020 ↗
35. Missero, C., and Antonini, D. (2014). Crosstalk among p53 family members in cutaneous carcinoma. Exp. Dermatol.Experimental Dermatology 23, 143-146. doi: NODOI PMID:NOPMID10.1111/exd.12320 ↗
36. Oren, M., and Rotter, V. (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2:, a001107. doi: NODOI PMID:NOPMID10.1101/cshperspect.a001107 ↗
37. Papadogianni, D., Soulitzis, N., Delakas, D., and Spandidos, D. A. (2014). Expression of p53 family genes in urinary bladder cancer: correlation with disease aggressiveness and recurrence. Tumour Biol. 35, 2481-2489. doi: NODOI PMID:NOPMID10.1007/s13277-013-1328-4 ↗
38. Ryan, K. M. (2011). p53 and autophagy in cancer: guardian of the genome meets guardian of the proteome. Eur. J. Cancer 47, 44-50. doi: NODOI PMID:NOPMID10.1016/j.ejca.2010.10.020 ↗
39. Samuels-Lev, Y., O'Connor, D. J., Bergamaschi, D., Trigiante, G., Hsieh, J. K., Zhong, S., et al. (2001). ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8, 781-794. doi: NODOI PMID:NOPMID10.1016/S1097-2765(01)00367-7 ↗
40. Santos-Pereira, J. M., Gallardo-Fuentes, L., Neto, A., Acemel, R. D., and Tena, J. J. (2019). Pioneer and repressive functions of p63 during zebrafish embryonic ectoderm specification. Nat. Commun. 10:, 3049. doi: NODOI PMID:NOPMID10.1038/s41467-019-11121-z ↗
41. Suzuki, K., and Matsubara, H. (2011). Recent advances in p53 research and cancer treatment. J. Biomed. Biotechnol. 2011:, 978312. doi: NODOI PMID:NOPMID10.1155/2011/978312 ↗
42. Vadakekolathu, J., Lai, C., Reeder, S., Church, S. E., Hood, T., Lourdusamy, A., et al. (2020). TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv. 4, 5011-5024. doi: NODOI PMID:NOPMID10.1182/bloodadvances.2020002512 ↗
43. Vayssade, M., Faridoni-Laurens, L., Benard, J., and Ahomadegbe, J. C. (2002). Expression of p53-family members and associated target molecules in breast cancer cell lines in response to vincristine treatment. Biochem. Pharmacol. 63, 1609-1617. doi: NODOI PMID:NOPMID10.1016/S0006-2952(02)00917-6 ↗
44. Vilgelm, A. E., Washington, M. K., Wei, J., Chen, H., Prassolov, V. S., and Zaika, A. I. (2010). Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol. Cancer Ther. 9, 693-705. doi: NODOI PMID:NOPMID10.1158/1535-7163.MCT-09-0912 ↗
45. Vousden, K. H., and Prives, C. (2009). Blinded by the light: the growing complexity of p53. Cell 137, 413-431. doi: NODOI PMID:NOPMID10.1016/j.cell.2009.04.037 ↗
46. Xie, X.-F., Yang, Q., Chi, J., Yang, X.-Z., and Wang, H.-Y. (2017). Prognostic values of apoptosis-stimulating P53-binding protein 1 and 2 and their relationships with clinical characteristics of esophageal squamous cell carcinoma patients: a retrospective study. Chin. J. Cancer 36:, 150160-0169. doi: NODOI PMID:NOPMID10.1186/s40880-016-0169-0 ↗
47. Yao, W., Qin, X., Qi, B., Lu, J., Guo, L., Liu, F., et al. (2014). Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma. Int. J. Clin. Exp. Pathol. 7, 7158-7163. doi: NODOI PMID:NOPMID